Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Nyxoah S.A.NASDAQ: NYXH

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -€14.63M, compared with -€21.2M a year earlier. Trailing-twelve-month EBITDA was -€77.16M.

Context

  • EBITDA amounted to 827.4% of revenue in FY2025, down 361.9 pp from a year earlier.
  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -€33.19M (+60.0%) for the fiscal year ending Dec 2026, a step up from the -54.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€14.63M+32.0% QoQ
Last fiscal yearDec 2025
-€82.9M-54.2% YoY
LTMMar 2026
-€77.16M-21.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.0%-53.8%-84.8 pp
1 year-54.2%+60.0%+114.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

EUR · from the income statement

Latest · FY2025
(82.9M) EUR
Year-over-year change
-54.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -21.4% is the 7th highest of 10, against a peer median of +9.1%.
  • EBITDA amounts to 472.8% of revenue for NYXH, versus a peer median of 50.9%.
NYXH Competitors
EBITDA for NYXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTMDUtah Medical Products, Inc.LTM Mar 2026$16.36M USD-9.1%-15.0%43.6%
KRMDKORU Medical Systems, Inc.LTM Mar 2026-$1.47M USD+67.9%—3.4%
STIMNeuronetics, Inc.LTM Mar 2026-$25.7M USD+34.0%—17.0%
OABIOmniAb, Inc.LTM Mar 2026-$33.82M USD+24.4%—117.0%
PREPrenetics Global LimitedLTM Mar 2026-$51.68M USD+9.1%—45.4%
TARAProtara Therapeutics, Inc.LTM Mar 2026-$62.94M USD-39.6%——
OSUROraSure Technologies, Inc.LTM Mar 2026-$63.7M USD-188.7%—56.4%
IVVDInvivyd, Inc.LTM Mar 2026-$75.72M USD+45.7%—135.5%
NYXHNyxoah S.A.LTM Mar 2026-€77.16M EUR-21.4%—472.8%
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$110.64M USD-31.7%—17902.8%
Peer median (excluding NYXH) —+9.1%-15.0%50.9%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue852K3.08M4.35M4.52M10.02M
Cost of Revenue303K1.15M1.66M1.55M3.69M
Gross Profit549K1.93M2.69M2.97M6.33M
Gross Margin64.4%62.7%61.9%65.7%63.1%
Research & Development5.95M15.86M27.66M34.33M42.82M
Selling, General & Admin11.11M18.86M20.65M28.46M46.44M
Operating Expenses26.79M34.43M47.79M61.78M89.27M
Depreciation & Amortization1.66M1.93M2.36M764K4.48M
EBITDA(22.59M)(27.89M)(42.08M)(53.77M)(82.9M)
EBITDA Margin-2651.5%-904.2%-967.8%-1189.2%-827.4%
Operating Income(26.24M)(32.5M)(45.1M)(58.81M)(82.94M)
Operating Margin-3080.0%-1053.8%-1037.3%-1300.8%-827.8%
Interest Income1K372K2.57M2.5M1.83M
Interest Expense386K237K1.21M1.9M1.69M
Other Income / Expenses1.6M2.44M445K2.38M(6.13M)
Income Before Tax(24.64M)(30.06M)(44.66M)(56.43M)(89.08M)
Pre-Tax Margin-2891.9%-974.6%-1027.1%-1248.2%-889.0%
Income Tax Expense2.98M1.17M(1.45M)2.8M1.01M
Net Income(27.62M)(31.23M)(43.21M)(59.24M)(90.09M)
Net Margin-3241.7%-1012.5%-993.8%-1310.2%-899.1%
EPS (Basic)(1.16)(1.21)(1.55)(1.81)(2.37)
EPS (Diluted)(1.16)(1.21)(1.55)(1.81)(2.37)
Weighted Avg Shares23.79M25.82M27.97M32.74M38.11M
Weighted Avg Shares (Diluted)23.79M25.82M27.97M32.74M38.11M

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.